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OBJECTIVE: Acute bronchiolitis is a leading cause of infant hospitalization and is most commonly caused by
respiratory syncytial virus. Etiological tests are not required for its diagnosis, but the influence of viral screening on
the therapeutic approach for acute bronchiolitis remains unclear.
METHODS: A historical cohort was performed to assess the impact of viral screening on drug prescriptions. The study
included infants up to one year of age who were hospitalized for bronchiolitis. Virus screening was performed using
immunofluorescence assays in nasopharyngeal aspirates. The clinical data were obtained from the patients’ medical
records. Therapeutic changes were considered to be associated with viral screening when made within 24 hours of
the release of the results.
RESULTS: The frequency of prescriptions for beta agonists, corticosteroids and antibiotics was high at the time of
admission and was similar among the 230 patients. The diagnosis of pneumonia and otitis was associated with the
introduction of antibiotics but did not influence antibiotics maintenance after the results of the virus screening
were obtained. Changes in the prescriptions were more frequent for the respiratory syncytial virus patients
compared to patients who had negative viral screening results (p= 0.004), especially the discontinuation of
antibiotics (p,0.001). The identification of respiratory syncytial virus was associated with the suspension of
antibiotics (p= 0.003), even after adjusting for confounding variables (p= 0.004); however, it did not influence the
suspension of beta-agonists or corticosteroids.
CONCLUSION: The identification of respiratory syncytial virus in infants with bronchiolitis was independently
associated with the discontinuation of antibiotics during hospitalization.
KEYWORDS: Bronchiolitis; Respiratory Syncytial Virus; Therapeutics; Fluorescent Antibody Technique.
Ferronato AˆE, Gilio AE, Ferraro AA, Paulis M, Vieira SE. Etiological diagnosis reduces the use of antibiotics in infants with bronchiolitis. Clinics.
2012;67(9):1001-1006.
Received for publication on February 7, 2012; First review completed on March 1, 2012; Accepted for publication on April 16, 2012
E-mail: sandra@hu.usp.br.
Tel.: 55 11 2661 8803
INTRODUCTION
Acute bronchiolitis (AB) is a leading cause of hospitaliza-
tion in children during their first year of life and is
responsible for over 120,000 annual hospitalizations in
developed countries (1). The morbidity for AB is even
greater in developing countries (2). Ecological studies show
that the hospitalization rates for AB have been increasing in
recent decades (3). In Brazil, the prevalence of bronchiolitis
is high, and hospitalization rates are increasing, according
to an analysis of government data (4,5).
Respiratory syncytial virus (RSV) is the main etiological
agent of AB and is responsible for up to 90% of cases during
the RSV season. RSV can be identified in nasopharyngeal
secretions using an immunofluorescence assay, culture, or
molecular biology techniques. According to international
clinical guidelines, these etiological tests are not required for
the diagnosis of bronchiolitis, as the diagnosis can be made
based on the clinical and epidemiological findings (6,7).
Conversely, the influence of the etiological investigation on
the therapeutic approach remains unclear in hospitalized
patients with a clinical diagnosis of bronchiolitis. Although
the recommended therapy consists of supportive measures,
such as oxygen therapy for hypoxemic patients, hydration
and maintaining an open airway, systemic antibiotics are
often used in patients with AB, as are corticosteroids and
bronchodilators (7,8). The request for etiological tests varies
widely, and the influence of the results of such tests on drug
prescription is rarely reported. A recent systematic review
selected four studies that enrolled children from emergency
departments. It suggested that viral test results may be
associated with a reduction of antibiotic use, but the
statistical power of the review was small because of the
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number of studies (9). Inpatient data are even scarcer. A
retrospective study reported a reduced time of antibiotics
use among those children who were found to be positive for
RSV (10).
This study examines the hypothesis that an etiological
diagnosis that is based on the results of an immunofluor-
escence assay (IFA), which is an accessible and affordable
method, may help guide the treatment of AB, thereby
reducing the use of systemic antibiotics. This study differs
from previous investigations due to the analysis of the
impact of viral testing results on the medical management of
hospitalized infants.
PATIENTS AND METHODS
A historical cohort study was conducted on hospitalized
infants in the Pediatric Clinic Division of the University
Hospital at Sa˜o Paulo University between January 2006 and
December 2007. This service provides regionalized care to
approximately 400,000 inhabitants of the western region
of Sa˜o Paulo. According to the hospital policy, infants
diagnosed with a lower respiratory tract infection upon
admission undergo nasopharyngeal aspirate (NPA) collec-
tion for respiratory virus screening. A commercial kit
(Biotrin International Ltd., Dublin/Ireland) is used for the
indirect IFA, which is standardized for the identification of
seven respiratory viruses (RSV, adenovirus, influenza A and
B, and parainfluenza 1, 2, and 3) and is used according to
the manufacturer’s instructions.
Only infants with the following criteria were included in
this study: 12 months of age or younger, a diagnosis of
bronchiolitis upon hospital discharge (according to the
International Classification of Diseases-9 and regardless of
other secondary diagnosis) and NPA collected within the
first day of hospitalization. Infants who presented the
following findings were excluded from the study: heart
diseases, chronic pulmonary diseases, prematurity (less
than 37 weeks of gestation), neuropathies, genetic syn-
dromes, immunodeficiencies, congenital airway malforma-
tions and recurrent episodes of wheezing. The patients’
medical records were analyzed by completing a standar-
dized protocol, including the collection of demographic
data, clinical findings, laboratory tests/chest X-ray on
admission and during the hospitalization and drug pre-
scriptions. The information on viral screening was collected
from physicians’ notes, which systematically included the
test result, date, and time. We have considered the time of
writing as the moment at which the physician became aware
of the result. The other laboratory tests, clinical features, and
diagnoses were also collected from the physicians’ notes.
The dates of hospitalization and discharge were obtained
from the informatics system. Information regarding the date
and time at which drug and oxygen therapy were started
and stopped was collected from prescription records, and
the prescriptions were considered to have been effectively
administered according to the nurse validation. In accor-
dance with standard procedures, changes to routine
prescriptions were made after discussion with the medical
staff during daily rounds. Changes in prescriptions that
were made within 24 hours of the recording of the viral
screening results were considered to be associated with
these results.
This study was approved by the IRB of the University
Hospital of the School of Medicine, University of Sa˜o Paulo.
Statistical analysis
The categorical variables are described as proportions, the
continuous parametric variables as means and standard
deviations, and the nonparametric variables as medians and
interquartile intervals. The chi-squared test was used to
assess the associations between the categorical variables.
Given the study design (cohort) and the high prevalence
rates of the outcomes, the effect size that was measured in
this study was the hazard ratio, which is an expression of
relative risk.
Two different regression models were built. In the first
model, the outcome variable was ‘‘introduction of antibiotic
therapy upon admission’’, and the clinical and laboratorial
characteristics were the explanatory variables. In the second
model, the outcome variable was ‘‘suspension of antibiotic
therapy after IFA result’’, the main exposure variable was
‘‘etiological diagnosis of RSV’’ and the other clinical and
laboratorial characteristics were the explanatory variables.
A univariate Poisson regression was used to calculate the
relative risk, and a multivariate model was built with the
variables that presented a p,0.10 in the univariate analyses
and other potential confounding variables, based on their
clinical importance. The p-value was fixed at p= 0.05 for
rejection of the null hypothesis. The statistical software
STATA 10.0H (StataCorp LP 2005, College Station, TX, USA)
was used for analysis.
The sample size was derived from convenience sampling
of 126 infants on antibiotic therapy (main outcome).
Assuming an increment from 10% to 50% in the rate of
discontinuation of antibiotics, according to the test results
and an alpha error probability of 5%, this sample size would
imply a statistical power over 90%.
RESULTS
Among 1,199 infants admitted to our hospital, 852 (71%)
were diagnosed with acute respiratory tract disease, and of
these, 283 (33%) met the criteria required for inclusion in
this study. Thirty-three infants were excluded according to
the previously defined criteria. Twenty cases could not be
analyzed due to incomplete data in their medical records.
Therefore, 230 medical records were studied (Figure 1).
The mean age of the infants was four months (sd = 2.7).
There was a slight predominance of males (n = 129; 56%).
The highest incidence of AB and RSV identification
occurred between February and July.
The main diagnosis on admission to the hospital was acute
bronchiolitis (n=65; 72%). Blood was collected for culture for
aerobic and anaerobic bacteria in 149 (65%) cases, and bacterial
growth was observed in three (2%) of them (DNase-negative
Staphylococcus, Pseudomonas sp. and Streptococcus viridans). All
of these patients were treated with antibiotics.
The medications most often prescribed upon hospital
admission were beta-agonist inhalers, systemic corticoster-
oids and systemic antibiotics. The antibiotics most com-
monly prescribed were intravenous penicillin (n = 51; 40.5%)
and oral amoxicillin (n = 29; 23.1%). Other antibiotics
prescribed were macrolides (n = 17; 13.5%), cefuroxime
(n = 08; 6.2%), ceftriaxone (n= 4; 3.1%), combination oxacillin
and amikacin (n = 11; 8.7%), penicillin and amikacin (n = 4;
3.2%) ceftriaxone and macrolide (n = 1; 0.8%) and ceftriax-
one and oxacillin (n = 1; 0.8%). No follow-up laboratory
tests or chest X-rays were requested before changes in the
prescriptions were made. The results of the laboratory
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evaluation and monitoring of patients during their hospi-
talization are shown in Table 1. RSV was identified as the
sole agent in 64% of patients (RSV(+) group; n = 146); no
viruses could be identified in 28% of patients (VIRUS(-)
group). Other viruses were identified in 8% (19 patients:
parainfluenza 3 (n = 8), parainfluenza 1 (n = 2), adenovirus
(n = 3), influenza A (n = 1), influenza B (n = 1), co-detection
(n = 4)). Due to the limited number of cases and the
heterogeneity of the viral agents identified, this group
was not included in the comparative analysis. The average
time for the physician to become aware of the viral test
results was 40 hours after admission. No significant
differences in the frequency of drug prescription upon
admission were observed between the patients in the
VIRUS(-) and RSV(+) groups. Following the results of the
viral screening, changes in medical prescriptions for drugs
were most frequent in the RSV(+) group. These changes
consisted mainly of the discontinuation of antibiotic
therapy (Table 2). The time of antibiotic discontinuation
was, on average, 7.2 hours after the viral test result was
recorded in the medical records.
After the discontinuation of antibiotic therapy, two
patients from the VIRUS(-) group required reintroduction
of antibiotic therapy due to a worsening respiratory
condition and radiological alterations. Two patients in the
RSV(+) group also required the reintroduction of antibiotics
(one due to the diagnosis of nosocomial pneumonia and the
other due to acute otitis media). A sub-analysis was
performed in which these four patients were included in
the group with maintained antibiotic therapy, and the
Figure 1 - Flow chart of the patients selected for this study.
Table 1 - Description of the therapies prescribed and laboratory exams performed upon hospital admission and the
characteristics of the clinical courses of the 230 patients included in the study.
THERAPY AND EXAMS UPON ADMISSION
Medical records with information
n (%)
Beta-agonist inhalers - n (%)
Systemic corticosteroids - n (%)
Systemic antibiotics - n (%)
185 (80%)
119 (52%)
126 (55%)
230 (100)
230 (100)
230 (100)
Radiography with opacification - n (%)
Positive blood cultures - n (%)***
118 (54%)
03 (02%)
217 (94)
149 (65)
Pulse oximetry - median (p25–p75) 89% (87–93) 195 (85)
C-reactive protein* - median (p25–p75)
Leukocytes** - median (p25–p75)
11 (5–27.25)
11,100 (7,900–15,150)
112 (49)
149 (65)
Clinical course characteristics during hospitalization
ICU*** - n (%)
Time in ICU*** - median (p25–p75)
MV# - n (%)
Time in MV# - median (p25–p75)
39 (17%)
4 days (3–6)
16 (07%)
3.5 days (2.25–5.75)
230 (100)
230 (100)
230 (100)
230 (100)
Total time in O2
## - median (p25–p75) 4 days (2–6) 230 (100)
Hospitalization period - median (p25–p75) 6 days (4–8) 230 (100)
*Values in mg/dL; **peripheral leukocyte count in cells/mL; ***ICU= intensive care unit; #MV=mechanical ventilation; ##O2=oxygen therapy.
CLINICS 2012;67(9):1001-1006 Bronchiolitis etiology and antibiotics
Ferronato AˆE et al.
1003
results revealed that the discontinuation of antibiotic
therapy was also predominant in patients from the RSV(+)
group (31.2% vs. 6.3%; p,0.001).
The introduction of antibiotic therapy upon admission to
the hospital was associated with an age over 6 months, the
presence of fever, thoracic radiography showing signs of
opacification, diagnosis of acute otitis media (AOM) and
pneumonia. After adjustment, according to the multivariate
analysis, only the diagnoses of AOM and pneumonia were
independent factors that predicted the introduction of
antibiotic therapy (Table 3).
In the univariate analysis, the presence of RSV was the
only variable associated with the discontinuation of anti-
biotic therapy. After adjustment for confounding factors, the
etiological diagnosis of RSV remained the sole independent
determinant of the discontinuation of antibiotic therapy
(Table 4).
DISCUSSION
The etiological diagnosis of RSV infection using IFA was
an independent factor associated with the discontinuation
of antibiotic therapy, which, based on clinical findings, was
prescribed upon admission to hospitalized infants with
bronchiolitis. The results of respiratory virus screening had
no impact on the use of bronchodilators and corticosteroids.
The results of this study suggest that an etiological
diagnosis is an objective and useful parameter in clinical
practice for bronchiolitis treatment.
The high frequencies of the prescription of antibiotics
(55%), bronchodilators (80%) and corticosteroids (52%) for
the initial treatment of infants with bronchiolitis indicate
the difficulty in promoting a therapeutic approach based
on scientific evidence. As in this study, the practice of
prescribing these drugs has also been reported in other
Table 2 - Medications prescribed upon admission to the hospital and drug discontinuation after virus screening for
patients in the VIRUS(-) and RSV(+) groups.
Medications Prescribed Upon Admission VIRUS(-) RSV(+) p-value
n=65 (100%) n=146 (100%)
Antibiotics 34 (52%) 75 (52%) 0.90
Corticosteroids 27 (42%) 81 (55%) 0.61
Beta-Agonist 48 (74%) 124 (85%) 0.06
Changes in drug prescriptions VIRUS(-) RSV(+) p-value
n=65 (100%) n=146 (100%)
Any drug discontinuation# 11 (17%) 54 (37%) 0.004
Discontinuation of antibiotics 06 (09%) 47 (32%) ,0.001
Discontinuation of corticosteroids 06 (09%) 10 (06%) 0.546
Discontinuation of beta-agonists 00 (00%) 02 (01%) 0.343
*Chi-squared test; #Any discontinuation in antibiotics and/or corticosteroids and/or beta agonists.
Table 3 - Univariate and multivariate analyses of the possible determinants of the introduction of antibiotic therapy
upon admission of the 230 patients included in the study.
Category
Antibiotic therapy
not introduced
n=104
(45.2%)
Antibiotic therapy
introduced
n=126
(54.8%) Univariate Analyses Multivariate Analyses
RR 95% CI p-value RR 95% CI p-value
RSV (+)* 71 (48.6) 75 (51.4) 0.85 0.59-1.21 0.357 - -
Age . 6 months 08 (20.5) 31 (79.5) 1.60 1.07-2.40 0.023 0.95 0.61-1.48 0.808
Male 56 (43.4) 73 (56.6) 0.93 0.65-1.32 0.676 - -
Fever on admission 56 (37.3) 94 (62.7) 1.57 1.05-2.34 0.028 0.93 0.60-1.44 0.745
Thoracic radiography with
opacification
18 (18.2) 81 (81.8) 2.41 1.65-3.52 ,0.001 1.48 0.94-2.32 0.091
ICU 14 (35.9) 25 (64.1) 1.21 0.78-1.88 0.389 - -
MV 02 (12.5) 14 (87.5) 1.67 0.96-2.91 0.070 1.30 0.74-2.28 0.370
AOM 00 (00.0) 12 (100) 1.91 1.05-3.47 0.033 4.66 2.28-9.51 ,0.001
Pneumonia 01 (1.1) 94 (98.9) 4.17 2.79-6.23 ,0.001 4.16 2.53-6.85 ,0.001
Leukocyte count*
,9,000
9-13,000
.13,000
15 (31.3)
15 (32.6)
16 (29.1)
33 (68.7)
31 (67.4)
39 (70.9)
1.02 0.81-1.28 0.890 - -
Oximetry %
mean (sd)
91 (0.4) 89 (0.4) 0.96 0.92-1.01 0.101 - -
VIRUS(+) = etiological diagnosis of infection with any respiratory virus; RSV(+) = etiological diagnosis of infection with respiratory syncytial virus; *Result
unavailable at the moment of introduction of antibiotic therapy; ICU= intensive care unit; MV=mechanical ventilation; AOM=diagnosis of acute otitis
media; RR= relative risk; #Number of cells/ml; ##Oximetry was analyzed as a continuous variable, whereas the other variables were categorized.
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countries, despite current clinical guidelines (7). However,
the use of ineffective or controversial therapies exposes the
patient to adverse effects. In a retrospective study of more
than 17,000 children under the age of one who were
hospitalized with bronchiolitis, the use of antibiotics,
bronchodilators and corticosteroids (45% of patients) was
associated with longer hospital stays (9). Additionally, the
inappropriate use of antibiotics may increase the risk of
bacterial resistance and the cost of hospitalization (12).
In this study, despite the high rate of antibiotic use, viral
screening contributed to the suspension of antibiotic
therapy in most cases and served as a valuable tool for the
adjustment of medical management. After adjusting for
other possible causes for the suspension of antibiotic
therapy, especially those that were relevant for the
introduction of therapy, such as the diagnosis of otitis and
pneumonia, the presence of RSV remained the sole
independent factor that influenced this change in the
therapeutic approach. We observed that other repeated
laboratorial and radiological tests were not considered
important for this clinical decision because none of them
were requested before the changes in the prescriptions were
performed. The test used for virus identification is highly
sensitive for RSV identification and is economically viable
and easily performed for hospitalized patients. Its predic-
tive value for RSV varies according to the epidemiological
scenario, and it is higher during peak seasonal periods for
the agent (13). Although its sensitivity is not as high for
other possible agents, such as adenovirus and influenza
virus, this test is useful for AB cases, given that RSV is the
predominant etiological agent. A recent study has shown
that the use of molecular techniques improves the viral test
sensitivity to other agents, such as human rhinovirus, but it
does not influence the detection of RSV in cases of
bronchiolitis (14).
The viral test results were added to medical records
during the second day of hospitalization, and the disconti-
nuation of antibiotics occurred within the next few hours.
This finding confirms the association between the physi-
cian’s awareness of the results and a change in the drug
prescription during the next round and suggests that the
viral test is a useful tool at the beginning of hospitalization.
Information regarding the impact of the etiological
investigation on the medical management of hospitalized
patients with AB is scarce, although in the in-hospital
environment, virus screening may be useful to reduce the
rates of nosocomial virus infections (6). Previous findings
also indicate some benefit of the use of viral screening in
therapeutic practice. Byington et al. analyzed the impact of a
rapid diagnostic test for respiratory viruses on antibiotic use
in a children’s hospital during two annual winter seasons.
In the first season, virus detection was associated with
shorter durations of intravenous antibiotic therapy (mean
2.4 vs. 4.0 days) and oral antibiotic therapy (0.25 vs. 2.5 days)
and fewer discharge prescriptions of oral antibiotics (37%
vs. 52%) compared with virus-negative patients. During the
second season, virus detection was associated with lower
rates of intravenous antibiotic prescription than in the first
season (26% vs. 44%), suggesting that the virus test
contributed for a more accurate management of AB at that
hospital (10). A systematic review concluded that the
current evidence is insufficient but promising regarding
the usefulness of viral screening in reducing the use of
antibiotics in the pediatric emergency department (9).
According to our results, the factors associated with the
introduction of antibiotic therapy upon admission to the
hospital were those that might suggest bacterial etiology.
The antibiotic therapy was most often prescribed for
patients over six months of age and for those with fever,
which may suggest that the pediatricians were more
Table 4 - Univariate and multivariate analyses of the possible determinants of the discontinuation of antibiotics during
the hospitalization of 109 patients from the VIRUS(-) and RSV(+) groups who received an initial prescription of antibiotic
therapy.
Univariate Analyses
Multivariate
Analyses
Category
Total number of
cases
Antibiotic therapy
discontinued
n (%)
Antibiotic
therapy
maintained
n (%) RR 95% CI p-value RR 95% CI p-value
RSV (+) 75 47 (62.7) 28(37.3) 3.55 1.52-8.31 0.003 3.58 1.51-8.50 0.004
Age . 6 months 83 43 (51.8) 40 (48.2) 0.74 0.37-1.48 0.396 0.68 0.33-1.41 0.300
Male 63 29(46.0) 34(54.0) 1.13 0.66-1.95 0.650 - -
Fever on admission 80 39 (48.7) 41(51.3) 0.87 0.47-1.61 0.662 - -
Fever for more than
24 h after admission
47 22 (46.8) 25 (53.2) 0.97 0.74-1.27 0.813 0.94 0.71-1.26 0.697
Thoracic radiography
with opacification
70 36(51.4) 34(49.6) 1.17 0.64-2.13 0.618 - -
ICU 23 11(47.8) 12(52.2) 0.98 0.50-1.90 0.951 - -
MV 12 5(41.7) 7(58.3) 0.84 0.34-2.12 0.714 - -
AOM 12 2(16.7) 10(83.3) 0.32 0.08-1.30 0.111 0.47 0.10-2.19 0.311
Pneumonia 82 43(52.4) 39(47.6) 1.42 0.71-2.82 0.322 1.12 0.53-2.39 0.764
Leukocyte count*
,9,000
9-13,000
.13,000
28
28
30
14(50.0)
13(46.4)
14(46.7)
14(50.0)
15(53.6)
16(53.3)
0.97 0.67-1.40 0.856 - -
Oximetry %
mean (sd)
93 89 (0.6) 90 (0.6) 0.98 0.91-1.05 0.522 - -
RSV(+) = etiological diagnosis of infection by the respiratory syncytial virus; ICU= intensive care unit; MV=mechanical ventilation; AOM=diagnosis of
acute otitis media; *Number of cells/ml; RR= relative risk; #Risk reduction for each change in category.
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confident in their initial diagnosis of viral bronchiolitis in
infants in their first six months of life without fever.
However, the etiological diagnosis of RSV allowed for
suspension of antibiotic therapy, even in older infants and
in the presence of fever. Although RSV can frequently cause
pneumonia and AOM, these diagnoses were strong indica-
tors for the prescription of antibiotics (15). Nonetheless,
these factors did not influence the suspension of antibiotic
therapy following a positive screening result for RSV. In the
population selected for this study, the inclusion criteria
were selective for bronchiolitis, which explains the low rate
of positivity of the blood cultures (2%). Similar to these
results, other studies have suggested that the occurrence of
bacterial infection in infants with bronchiolitis is not
common (16).
This study has some limitations due to its retrospective
nature. The influence of the experience and qualification of
the physician responsible for the medical management
could not be assessed. However, according to routine
procedures at the hospital, decisions regarding the medical
management of infants with bronchiolitis were made by the
medical staff, which is homogenous as a result of the high
frequency of this disease and the staff’s clinical and research
experience in this field of study (17-19).
Even though IFA enables the diagnosis of other respira-
tory viruses, a statistical analysis of these cases could not be
performed due to their low frequencies, the heterogeneity of
the viral agents that we found and the fact that the medical
management for other viral infections not caused by RSV
could differ. Further studies with an appropriate casuistic
are necessary to perform such an analysis.
We excluded patients with chronic diseases and pre-
maturity to avoid distortions in the analysis because these
comorbidities themselves influence antibiotic use. The
number of such cases in a general hospital would not allow
us to analyze them separately. Therefore, our results cannot
be generalized to these patients. The obtained results also
may not be extrapolated to outpatients. However, a
systematic review suggested that viral screening as part of
the emergency service for children with respiratory infec-
tions may be promising (9).
The results of this study suggest that the etiological
diagnosis of RSV infection in hospitalized infants with
bronchiolitis was independently associated with the dis-
continuation of antibiotic therapy. Affordable laboratory
methods, such as the IFA, for the identification of viruses
may help decrease inappropriate prescription of antibiotics
for these infants. This may contribute to a more cost-
effective approach and to a reduction in the inappropriate
use of antibiotics for inpatients. Future prospective studies
are needed to minimize the impact of bias and to confirm
these results.
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